IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

h re Application of: Nicholas M. Valinate et al.

Serial No.:

10/762,873

Group Art Unit: 1614

Filed:

January 21, 2004

Examiner: to be assigned

For:

USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE

POTENTIATION

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 AND §1.97(b)(3)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The citations listed on the enclosed Information Disclosure Form PTO-1449 may be material to the examination of the above-identified patent application. Therefore, Applicants submit these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56 and §1.97(b)(3). The Examiner is requested to make these citations of official record in the present application.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

This Information Disclosure Statement under 37 C.F.R. §1.56 and §1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

> I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class mail in an envelope addressed to: Mail Stop

Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450,

1

The Commissioner is hereby authorized to charge any fees in connection with this Information Disclosure Statement to Deposit Account No. 03-1664. This, however, is not an authorization for payment of Issue Fee.

Respectfully submitted,

By:

Steven W. Collier Attorney for Applicants Reg. No. 42,429

November 4, 2004

CHIRON CORPORATION Intellectual Property - R440 P.O. Box 8097 Emeryville, California (510) 923-3774 (510) 655-3542 (fax)

NOV O 8 ZULA		Serial No.: 10/762,873
FORM PTO-1444 U.S. Dec. of Commerce (Modified) Paten and Trademark Office	Atty. Docket No.: 20203.003	Serial No.
(Modified) Pater Hull Hademark INFORMATION DISCLOSURE CITATION	Applicants: Nicholas Valiante	
	Filing Date: January 21, 2004	Group: to be assigned
(Use several sheets if necessary)	Filling	

			ប.ន	. PATENT DOCUMENTS			<u> </u>
*Examiner Initial AA AB AC AD AE AF AG AH	T :	Document Number 2002/0164341	Date	Name	Class	Subclass	Filing Date If Appropriate
				newig at al	424	184.1	12/18/01
	AA		11/07/02	Davis et al.			07/25/02
	1,5	2002/0197269	12/26/02	Lingnau <u>et al</u> .	424	185.1	1 07/23/02
	+	+	02/21/89	Cantrell	424	282.1	04/15/86
	AC	4,806,352 02/21/89		424	78.31	09/27/89	
	AD	5,026,543	06/25/91	Riijke		+	10/17/07
		5 000 546	06/25/91	6/25/91 Hilgers et al.	424	280.1	12/17/87
		5,026,546	_+	Baker et al.	514	250	11/19/93
		5,441,955	08/15/95	Baker cc gar.		308	09/28/99
	+	6,284,772	09/04/01	Pitzer et al.	514	1300	
			03/11/03		514	308	05/08/01
		6,531,487	- 03, 22, 22	 			
	1	1	1				

FOREIGN PATENT DOCUMENTS lation Trans-Subclass Class Country No Document Number Publ. Date 03/22/00 Europe 987,027 PCT 08/21/03 WO 03/069303 вв PCT 12/10/98 WO 98/55495 ВC 04/23/98 WO 98/16247 ВD

		THER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)			
OTHER CITATIONS (Including Author, 1223)					
CA		Warren et al., "Current Status of Immunological Adjuvants" Ann. Rev. Immunol. 4:369-388, 1986			
СВ		O'Hagan et al., "Recent Advantages in the Discovery and Delivery of Vaccine Adjuvants" Nature Review Discovery 2:727-735, 2003			
СС		Mitscher et al., "Antimicrobial Agents from Higher Plants" Heterocycles 15(2):1017-1019, 1981			
,					
	_+				

Examiner	Date Considered
	warm coo. Draw line through

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.